HK1024424A1 - Methods of therapeutic administration of anti-cd40l compounds - Google Patents

Methods of therapeutic administration of anti-cd40l compounds

Info

Publication number
HK1024424A1
HK1024424A1 HK00103914A HK00103914A HK1024424A1 HK 1024424 A1 HK1024424 A1 HK 1024424A1 HK 00103914 A HK00103914 A HK 00103914A HK 00103914 A HK00103914 A HK 00103914A HK 1024424 A1 HK1024424 A1 HK 1024424A1
Authority
HK
Hong Kong
Prior art keywords
methods
therapeutic administration
cd40l compounds
cd40l
compounds
Prior art date
Application number
HK00103914A
Other languages
English (en)
Inventor
Susan L Kalled
David W Thomas
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of HK1024424A1 publication Critical patent/HK1024424A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HK00103914A 1997-01-10 2000-06-28 Methods of therapeutic administration of anti-cd40l compounds HK1024424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (en) 1997-01-10 1998-01-09 Methods of therapeutic administration of anti-cd40l compounds

Publications (1)

Publication Number Publication Date
HK1024424A1 true HK1024424A1 (en) 2000-10-13

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103914A HK1024424A1 (en) 1997-01-10 2000-06-28 Methods of therapeutic administration of anti-cd40l compounds

Country Status (21)

Country Link
US (2) US20020071840A1 (pl)
EP (1) EP0966302B1 (pl)
JP (1) JP2001508450A (pl)
KR (2) KR100632846B1 (pl)
CN (1) CN1248921A (pl)
AT (1) ATE356634T1 (pl)
AU (1) AU721697B2 (pl)
BR (1) BR9807471A (pl)
CA (1) CA2277223A1 (pl)
CZ (1) CZ244399A3 (pl)
DE (1) DE69837322T2 (pl)
EA (1) EA001426B1 (pl)
EE (1) EE9900275A (pl)
HK (1) HK1024424A1 (pl)
IL (1) IL130785A0 (pl)
IS (1) IS5101A (pl)
NO (1) NO993275L (pl)
NZ (1) NZ337073A (pl)
PL (1) PL193966B1 (pl)
TR (1) TR199902192T2 (pl)
WO (1) WO1998030241A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CN1202864C (zh) * 1997-05-17 2005-05-25 拜奥根有限公司 Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途
DE69825473T2 (de) * 1997-06-20 2005-08-04 Biogen Idec Ma Inc., Cambridge Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
US20030170231A1 (en) * 2000-03-06 2003-09-11 Toshihiko Yamauchi Remedies and preventives for antiphospholipid antibody syndrome
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CN100494182C (zh) 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
ES2371635T3 (es) * 2002-11-21 2012-01-05 Genzyme Corporation Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes.
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DK0721346T3 (da) * 1993-09-02 1999-03-22 Dartmouth College Fremgangsmåde til induktion af antigenspecifik T-celletolerance
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
AU7643094A (en) * 1993-09-02 1995-03-22 Trustees Of Dartmouth College Methods of prolonged suppression of humoral immunity
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
US20020071840A1 (en) 2002-06-13
US20050158314A1 (en) 2005-07-21
PL334500A1 (en) 2000-02-28
CA2277223A1 (en) 1998-07-16
EA199900633A1 (ru) 2000-02-28
KR20050088494A (ko) 2005-09-06
EE9900275A (et) 2000-02-15
NZ337073A (en) 2001-01-26
BR9807471A (pt) 2000-03-21
EP0966302A1 (en) 1999-12-29
KR100632846B1 (ko) 2006-10-16
AU5735398A (en) 1998-08-03
WO1998030241A1 (en) 1998-07-16
CN1248921A (zh) 2000-03-29
IS5101A (is) 1999-06-30
DE69837322D1 (de) 2007-04-26
PL193966B1 (pl) 2007-04-30
KR20000070035A (ko) 2000-11-25
TR199902192T2 (xx) 1999-12-21
CZ244399A3 (cs) 1999-10-13
JP2001508450A (ja) 2001-06-26
NO993275D0 (no) 1999-07-01
ATE356634T1 (de) 2007-04-15
IL130785A0 (en) 2001-01-28
EP0966302B1 (en) 2007-03-14
AU721697B2 (en) 2000-07-13
EA001426B1 (ru) 2001-02-26
DE69837322T2 (de) 2007-11-22
NO993275L (no) 1999-09-09

Similar Documents

Publication Publication Date Title
HK1024424A1 (en) Methods of therapeutic administration of anti-cd40l compounds
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
HK1051684A1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
IL207358A (en) Combined treatments for B-cell lymphomas that include the provision of anti-cd20 antibody
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
IL192287A0 (en) Pharmaceutical compositions and methods for use
HK1034446A1 (en) Therapeutic agents.
HK1043315A1 (en) Triazineone compounds for treating diseases due tosarcosystis, neospora and toxoplasma.
HUP0001263A2 (hu) Eljárások anti-CD4OL vegyületek gyógyászati alkalmazásaira
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110109